No Prescription |
 |
 | ||
|
SORBITRATE Dilatrate SR |
|
| ||
No Prescription » Prescription Drugs 15 » SORBITRATE Dilatrate SR Isosorbide is used to prevent or treat chest pain (angina). It works by relaxing the blood vessels to the heart so the blood and oxygen supply to the heart is increased.Isosorbide controls chest pain but does not cure it. Continue to take isosorbide even if you feel well. Do not stop taking isosorbide without talking to your doctor. Stopping the drug abruptly may cause chest pain.Isosorbide tablets are also used with other drugs to treat congestive heart failure. Buy SORBITRATE Dilatrate SR and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About SORBITRATE Dilatrate SR: Product Type: Prescription Drugs 15 SORBITRATE ( Dilatrate SR Isordil Sorbitrate Generic Isosorbide Dinitrate ) SORBITRATE (Dilatrate SR Isordil Sorbitrate Generic Isosorbide Dinitrate) Dilatrate SR Isordil Sorbitrate Generic Isosorbide Dinitrate 10mg Tabs Dilatrate SR Isordil Sorbitrate Generic Isosorbide Dinitrate SORBITRATE
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
